Biocon Launches Biosimilar Semglee
Branded and unbranded versions of the interchangeable biosimilar to treat patients with diabetes are now available.
Biocon Biologics and Viatris have launched the biosimilar Semglee (insulin glargine-yfgn) injection, a branded product, and Insulin Glargine (insulin glargine-yfgn) injection, an unbranded product, to help control high blood sugar in adult and pediatric patients with type 1 diabetes and adults with type 2 diabetes. Both biosimilar products are available in a vial and in prefilled pens.
Related: FDA Approves First Interchangeable Biosimilar Insulin
In July 2021, the FDA approved Semglee as interchangeable for the reference brand, Lantus (insulin glargine). An interchangeable biosimilar product may be substituted for the reference product at the pharmacy level.
Several PBMs, including Express Scripts and Prime Therapeutics, have already announced that they will exclude Lantus on their formularies and add Semglee as a preferred product.
Semglee and the nonbranded product were co-developed by Biocon Biologics and Viatris. The currently marketed non-interchangeable Semglee will be phased out by the end of the 2021, according to a statement from the companies.
Viatris has established several programs to help to help with patient access, including a patient assistance program, a copay program that limits out-of-pocket expenses, and a program for Medicare Part D that limits out-of-pocket expenses to no more than $35 a month.
AstraZeneca, Daiichi Sankyo Submit New BLA for Datopotamab in Lung Cancer
November 12th 2024After feedback from the FDA, the companies have voluntarily withdrawn the previous biologics licensing application for datopotamab deruxtecan for patients with advanced or metastatic nonsquamous non-small cell lung cancer.
Read More
Diabetes Management & Telehealth with Leslie Kolb
June 11th 2020Association of Diabetes Care and Education Specialists, chief science and practice officer, Leslie Kolb chats with MHE Associate Editor Briana Contreras in MHE's newest podcast Tuning into the C-Suite about diabetes management and how it's affected by the use of telehealth, especially during the current and trying times of the COVID-19 pandemic.
Listen
Skyrizi Overtakes Humira in U.S. Sales Numbers
November 8th 2024For the first time, Skyrizi has replaced Humira as AbbVie’s sales driver, largely due to companies encouraging “product hopping” to avoid competition, creating concerns for the sustainability of the burgeoning adalimumab biosimilar market.
Read More
